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Abstract
Background: Abnormal Savda Munziq (ASMq), a traditional uyghur medicine, has shown anti-tumour properties in
vitro. it was showed that total flavonoids of ASMq could inhibit the proliferation and enhance the antioxidant
ability of human cervix cancer HeLa cell. This study attempts to confirm these effects on the transplanted cervical
cancer (U27) mouse model in vivo.
Methods: Forty eight Kunming mice were randomly divided in to six groups: normal control group (Control group),
U27 tumor model group (Model group), cyclophosphamide administration group (CTX group),low-dose ASMq group
(ASMq.L group), medium-dose ASMq group (ASMq.M group), and high-dose ASMq group (ASMq.H group). The five
groups except normal control group transplanted with cervical cancer (U27) cells. We observed mice tumor inhibition
rate and conducted the histopathological analysisUsing the western blot assay, the expression of TGF-β1 and TNF-α
protein in transplanted cervical cancer U27 tumor tissue were detected.
Results: The tumor inhibition rates of CTX group, ASMq.L group, ASMq.M group, and ASMq.H group were 72.21, 31.27,
60.53 and 51.94% respectively, has obvious antitumor effect. ASMq significantly promote the spleen tlymphocyte
proliferation of transplanted cervical cancer U27 mice. Invasive growth and diffusion rate in tumor tissue were
accelerate in the transplanted cervical cancer U27 model group. Tumor tissue necrosis of tumor cells are smaller in
the medium, high dosage group. Compared with the U27 model group, the expression levels of TGF-β1 protein
and TNF-α protein expression exhibited statistically significant decreased in the mice tumor tissues in the CTX
administration group and the ASMq administration group.
Conclusions: ASMq has some antitumor effects on U27 model mice in vivo, The effects are achieved not only by
improving the immune function of U27 model mice, but also by inhibiting the expression levels of TGF-β1 protein
while promoting the expression levels of TNF-α protein.
Background
Cervical cancer is a high-incidence malignancy in
women, it has been severely impacts the lives of women
worldwide [1, 2]. According to literature, over 500,000
new cases occur globally every year, approximately half
of them are fatal [3]. The morbidity and mortality rates
of Xinjiang Uigur women are higher than those of other
ethnic women in Xinjiang. In fact, the mortality rate
ranks number 1 in Chinese minorities.
In the earliest Greco-Arab medical texts, Hippocratic
Corpus, Hippocrates proposed a series of theorems based
on liquids and their volumes. Hippocrates suggested that
the human body is primarily comprised of four Hilits, or
the “body fluids”, which includes blood (Kan), black bile
(Savda), yellow bile (Safra), and phlegm. Each of these
body fluids has its own unique color (red, black, yellow,
and white), viscosity, and basic qualities. After the onset of
disease, a person exhibits an excess of body fluids that
disrupts the normal balance [4]. Uigur medicine, one of
the three traditional types of Chinese medicine, originated
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from Greco-Arab medicine [5]. Uigur medicine also holds
that the human body is comprised of four kinds of body
fluids. Abnormal savda is considered the final product of
all of body fluids in the presence of abnormal changes. In
addition, in Uigur medicine, tumor development is related
to the formation of abnormal savda. Since abnormal savda
is thick in texture, it can easily result in biliary stasis if
deposited in vessel walls, leading to cancer and other
intractable diseases. Abnormal Savda Munziq (ASMq) is a
natural compound prepared using ten types of herbs,
including Glycyrrhiza uralensis Fisch., Adiantum capillus-
veneris L., Euphorbia humifusa Willd., Alhagi pseudalhagi
Desv. (as show in Table 1) [6]. In the previous studies, it
was showed that total flavonoids of ASMq can inhibit the
proliferation and enhance the antioxidant ability of human
cervix cancer HeLa cell [7]. In addition, the Abnormal
Savda Munziq had obvious inhibition effect on liver cancer
and breast cancer, and the effect of Abnormal Savda Mun-
ziq was strong scavenging hydroxyl free radical, protecting
DNA oxidative damage and inducing apoptosis [8–14].
In this study, the anti-tumor effects of ASMq on U27
tumor model mice were investigated, providing an ex-
perimental basis for the clinical treatment of cervical
cancer with the Uigur drug ASMq and contributing to
the recognition of its anti-tumor effects on U27 tumors.
Methods
Animals and cell lines
A total of 48 healthy Kunming mice (24 male, 24 female)
weighing 20 ± 2 g, were provided by the Xinjiang
Medical University Experimental Animal Center (license
number: SCXK (Xin) 2011-0004). The U27 cervical can-
cer cell lines were purchased from Wuhan University.
Laboratory instruments and reagents
The analytical balance (Model: AL204) and electronic
balance (Model: PL602S) were purchased from Shanghai
Mettler-Toledo Instruments Co., Ltd. The -80 °C ultra-
low temperature freezer was purchased from Haier,
China. The low temperature refrigerated centrifuge
(Model: FRESCO 17) and microplate reader (Model:
MULTISKAN MK3) were purchased from Thermo.
The shaker (Model: TS-8), vortex (Model: QL-861),
thermostat (Model: GL-150B), and magnetic stirrer
(Model: GL-3250C) were purchased from Kylin-Bell
Lab Instruments Co., Ltd. The electrophoresis, mem-
brane transfer device Tanon (Model: VE-180), and scan-
ner (Model: MFC7450) were purchased from Brother.
The Hypersensitivity ECL Chemiluminescence Kit (Cat.
No.: B0018) and BCA Protein Assay Kit (Cat. No.:
P0012) were purchased from Beyotime. β-Actin (Size:
0.2 ml) was purchased from Boster. The medical X-ray
films (Specification: Super RX) were purchased from
Fuji. TGF-β1 (Size: 100 μg, Item No: A1-29020) and
TNF-α antibodies (Size: 100 μg, Item No: PA5-19810)
were purchased from Thermo Scientific. ASMq was
purchased from Xinjiang Cicon Habo Uighur Medicine
Ltd. Corporation. cyclophosphamide (Batch number:
13122625) was purchased from Jiangsu Hengrui Medi-
cine Co., Ltd. Saline (Batch number: 1311161) was pur-
chased from Sinopharm Xinjiang Pharmaceutical Co.,
Ltd. Hematoxylin and Eosin Staining Kit, Matrigel (BD
Biosciences, USA).
Animal grouping
The 48 healthy Kunming mice were randomly divided
into six groups of eight mice (four male, four female),
including the normal control group, the U27 tumor
model group, the CTX administration group, and the
low-, medium-, and high-dose ASMq groups.
Construction of the U27 tumor mouse model
The 40 mice in the groups other than the normal con-
trol group were used construct the transplanted cervical
Table 1 Plants used in Uyghur herbal preparation Abnormal Savda Munziq (ASMq)
Uyghur Name Latin name Family Part used
Pirsiyavxan Adiantum capillus-veneris L. Adiantaceae Whole plant
Kök tantak Alhagi pseudalhagi (Bieb.) Desv. Fabaceae Branch secretion
Gavziban Anchusa italica Retz. Boraginaceae Whole plant
Serbistan Cordia dichotoma G.Forst. Boraginaceae Fruit
Yalmankülak Euphorbia humifusa Willd. Euphorbia maculata L. Euphorbiaceae Whole plant
Arpabidiyan Foeniculum vulgare Mill. Apiaceae Fruit
Qüqük buya Glycyrrhiza uralensis Fisch. ex DC. Fabaceae Radix or rhizoma
Üstihuddus Lavandula angustifolia Mill. Lamiaceae Aerial parts
Badrenjiboye hindi Melissa officinalis L. Lamiaceae Whole plant
Qilan Ziziphus jujuba Mill. Rhamnaceae Fruit
Glycyrrhiza inflata Batalin Fabaceae Radix or rhizoma
Glycyrrhiza glabra L. Fabaceae Radix or rhizoma
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carcinoma (U27) tumor model. The following experi-
mental method was implemented [15]. Ascitic fluid
(milk white color) was drawn from the U27 Kunming
mice 7 days after inoculation (intraperitoneal injection
of 0.2 mL 1.0 × 107 cfu/mL cells) and diluted to a con-
centration of 1.0 × 107 cfu/mL with saline sterilized at
high pressure. 0.2 mL of ascites suspension was injected
into the left forelimb axilla of each mouse. The entire
process was conducted under sterile conditions within
30 min. After 24 h, the drugs were administered ac-
cording to body weight. 0.2 mL/10 g (equal amounts
of ) saline were administered to the control group and
U27 tumor model group via gavage every day. In
addition, the mice in the control group and U27 tumor
were administered intraperitoneal injections of 0.2 mL/
10 g saline every other day. The mice in the CTX ad-
ministration group were administered 0.2 mL/10 g sa-
line via gavage every day and an intraperitoneal
injection of 30 mg/kg CTX every other day. The mice
in the low-, medium-, and high-dose ASMq groups
were administered 2, 4, and 8 g/kg ASMq, respectively,
via gavage every day and 0.2 mL/10 g intraperitoneal
injections of saline every other day. All of the mice
were provided with food and water, weighed every day,
and administered their respective medications via gav-
age for 10 continuous days.
Sample preparation
The Kunming mice were euthanized after continuous
gavage for 10 days. Then the tumor tissues of U27 and
the thymus, spleen, liver, kidneys each mouse were ex-
tracted. The tumor tissues were dissected into two por-
tions quickly, one was transferred into a frozen tube,
and the other portion was fixed in 10% formalin and
dehydrated for hematoxylin and eosin (HE) staining.
Determination of the tumor inhibition rate and the
spleen, thymus, liver, and kidney indexes
Tumor inhibition rate = [(the average tumor weight of
the tumor model group - the average tumor weight of
the treated group)/the average tumor weight of the
tumor model group] × 100%. Thymus index = thymus
weight (mg)/body weight (g). The spleen, liver, and kidney
indexes were calculated similarly [16].
Preparation and HE staining of the U27 tumor tissue
histological sections
The 10% formalin-fixed, dehydrated U27 tumor tissues
were embedded in paraffin and processed into 4 μm
paraffin sections. After HE staining, the sections were
cleared with xylene and mounted in neutral gum [17].
The cell morphology of U27 tumor tissue sample was
carefully observed under an optical microscope.
TGF-β1 and TNF-α protein expression in the U27 tumor
tissues
A small amount of each tumor tissue sample was
weighed into a homogenizer and combined with RIPA
lysis buffer. After homogenization, the tissue samples
were placed on ice in order to ensure thorough lysis.
Then, each sample was transferred into a centrifuge tube
and centrifuged at 4 °C pre-cold centrifuge at 12,000 r/
min for 5 min. The supernatant was collected for protein
concentration determination via the BCA method. First,
4 mL 10% resolving gel was prepared, and 4% stacking
gel was quickly poured into the gel sandwich. The sam-
ples were gently loaded into the gel wells. The electro-
phoresis apparatus was connected to the power supply
and run under constant voltage. First, the apparatus was
set at 80 V, or approximately 8 V/cm, until each sample
passed through the interface between the stacking gel
and resolving gel. Then, the apparatus was set to 120 V
until the dye reached an appropriate location. A PVDF
membrane was soaked in 100% methanol for 2–3 min,
then rinsed with water and Western transfer buffer twice
for 2 min. The membrane was kept in the transfer buf-
fer. Six layers of filter paper the same size as the gel were
cut and soaked in the transfer buffer. The protein was
transferred at 4 °C for 1 h. In addition, the membrane
was soaked in the blocking buffer at room temperature
and shaken slowly for 1 h. Then, the membrane was
added to the primary antibody and diluted in the block-
ing buffer at 4 °C overnight. After being washed three
times with the TBST buffer, the secondary antibody was
added and allowed to react for 2 h. Then, the membrane
was washed with the TBST buffer again in order to re-
move the free secondary antibody. Finally, the mem-
brane was exposed in the dark. The average values were
calculated after repeating this process three times.
Data processing and analysis
All of the data was tested for normality and homogen-
eity of variance before further analysis. Statistic analysis
was performed with SPSS17.0 One-way analysis of vari-
ance ANOVA and chi-square tests where experimental
data was indicated as mean ± SD. The mean difference is
considered significant at the p-value < 0.05 level.
Results
Effects of ASMq on the thymic, splenic, hepatic, and renal
weights of the U27 tumor mice
Compared to the normal control group, the thymic,
splenic, and renal weights of the U27 tumor model mice
are all lower (p < 0.05); the thymic, splenic, hepatic, and
renal weights of the CTX group are all decreased (p < 0.05);
the splenic, hepatic, and renal weights of the low-dose
ASMq group are all dropped (p < 0.05). In contrast, the
splenic and hepatic weights of the medium-dose ASMq
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group are increased (p < 0.05), while the renal weight is de-
creased (p < 0.05). Furthermore, the thymic and hepatic
weights of the high-dose ASMq group are both ele-
vated (p < 0.05). Compared to the U27 tumor model
group, the weights of all of the major organs in the
CTX group are decreased (p < 0.05), while the thymic,
splenic, and hepatic weights of the ASMq group are
increased (p < 0.05). Compared to the CTX group, the
weights of all of the major organs in the ASMq group
are elevated (p < 0.05), as shown in Table 2.
Effects of ASMq on the tumor inhibition rates and vital
organ indexes of the U27 tumor mice
The thymus, spleen, and liver indexes of the U27 tumor
model group are lower than those of the normal control
group (p < 0.05). In addition, the thymus, spleen, and
liver indexes of the CTX group are decreased signifi-
cantly (p < 0.05). The thymus, spleen, and kidney indexes
of the low-dose ASMq group are also decreased signifi-
cantly (p < 0.05). Likewise, the thymus, spleen, and kid-
ney indexes of the medium-dose ASMq group are
decreased (p < 0.05), while the thymus, spleen, and kid-
ney indexes of the high-dose ASMq group are decreased
significantly (p < 0.05). Compared to the U27 tumor
model group, the thymus, spleen, and liver indexes of
the CTX group are decreased significantly (p < 0.05),
while the kidney indexes of the CTX group are increased
(p < 0.05). Furthermore, the thymus, spleen, and kidney
indexes of the low- and medium-dose ASMq groups as
well as the spleen and kidney indexes of the high-dose
ASMq group are decreased (p < 0.05). Compared to the
CTX group, the thymus, spleen, and liver indexes of all
ASMq groups are increased significantly (p < 0.05), while
the kidney indexes of the ASMq groups are decreased
(p < 0.05), as shown in Table 3.
The tumor inhibition rates of the CTX group and the
ASMq.L group, ASMq.M group, and ASMq.H are ap-
proximately 72.21, 31.27, 60.53, and 51.94%, respectively.
Compared to the U27 tumor model group, the tumor
masses of the CTX group and all of the ASMq groups are
decreased significantly (p < 0.05). In contrast, compared to
the CTX group, the tumor masses of all of the ASMq
groups increased (p < 0.05), as shown in Table 4.
Effects of ASMq on the histological sections of the U27
tumor mice
The tumors in the U27 model group exhibited invasive
growth and rapid diffusion with high degrees of tumor
cell proliferation. The cells were uneven in size and
disordered, with different shades, large nuclei, less
cytoplasm, visible nuclear mitosis, light edema, and
infiltrated interstitial fluid containing a few inflamma-
tory cells, as shown in Fig. 1 (U27 Tumor Model
group). After the CTX treatment, the tumor cells ex-
hibited unclear structures with regional necrosis, clear
cell edema, and a large number of disintegrated granu-
lar cells, as shown in Fig. 1 (CTX group). After the
low-dose ASMq treatment, a large number of malig-
nant cells surrounded the necrotic tissue, with edema,
nuclear condensation, different shades, and clear inter-
stitial edema, as shown in Fig. 1 (ASMq.L group). After
the medium-dose ASMq treatment, the tumor cells dis-
played large areas of necrosis with slight liquefaction.
In addition, the cells at the borders of the necrotic tis-
sue disintegrated into granular cells with interstitial
edema, as shown in Fig. 1 (ASMq.M group). After the
high-dose ASMq treatment, the tumor cells demon-
strated regional necrosis, with shrunken cell volumes,
nuclear condensation, and clear interstitial edema occa-
sionally infiltrated with inflammatory cells, as shown in
Fig. 1 (ASMq.H group).
Effects of ASMq on TGF-β1 and TNF-α protein expression
in the tumor tissues of the U27 model mice
The TGF-β1 and TNF-α expression levels of the tumor
tissues were determined via the Western blot method.
The quantitative results are shown in Table 5. Compared
to the U27 tumor model group, the CTX group demon-
strates significantly reduced TGF-β1 and TNF-α protein
expression levels (P <0.05). In addition, the low-, medium-
, and high-dose ASMq groups all demonstrates decreased
TGF-β1 protein expression levels and significantly in-
creased TGF-α protein expression levels (p < 0.05).
Compared to the CTX group, the TGF-β1 expression
levels of the ASMq groups are decreased (p < 0.05),
while the TGF-α expression levels of the ASMq groups
are increased (p < 0.05). as shown in Fig. 2
Table 2 ASMq’s effect on the important organ weight of in each group mice (n = 8, x  s)
Group Dosage/(g/kg) Thymus weight Spleen weight Liver weight Kidney weight
Normal control group - 127.270 ± 3.382 187.160 ± 5.192 1788.910 ± 47.413 462.210 ± 29.221
U27 Tumot Model group - 112.369 ± 4.029* 166.252 ± 8.568* 1713.961 ± 49.607 440.741 ± 18.023*
CTX group 0.3 74.296 ± 13.993*△ 99.052 ± 23.571*△ 1373.506 ± 134.165*△ 401.114 ± 15.965*△
ASMq.L group 2 120.720 ± 6.131△▲ 174.750 ± 10.242*△▲ 1760.940 ± 141.710*△▲ 434.980 ± 18.858*▲
ASMq.M group 4 128.900 ± 4.822△▲ 199.030 ± 9.627*△▲ 1905.760 ± 79.073*△▲ 440.190 ± 22.025*▲
ASMq.H group 8 136.640 ± 7.524*△▲ 187.810 ± 11.047△▲ 1991.600 ± 167.884*△▲ 448.740 ± 22.692▲
Notes:*P < 0.05 compared with Normal control group;△P < 0.05 compared with U27 tumor model group;▲P < 0.05 compared with CTX group
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Discussion
In recent years, numerous studies concerning the anti-
tumor effects of ASMq have been conducted. In vitro
studies are indicated that ASMq could inhibit the cell
proliferation of breast cancer, liver cancer, lymphoma,
and cervical cancer cells as well as promotes apoptosis
[18–21]. However, very few reports concerning the in
vivo mechanisms of ASMq exist. Our research team
has been investigating the in vivo anti-tumor mecha-
nisms of ASMq for a long time. By studying the in vivo
mechanisms of ASMq, we found that ASMq shows a
certain levels of therapeutic effects on EAC and S180
tumor cell [22–24]. In order to investigate the in vivo
antitumor effects of ASMq on the U27 tumor mouse
model, this study focused on the tumor inhibition rate,
tumor histopathology, and TGF-β1 and TNF-a protein
expression levels of tumor tissues obtained from the
U27 tumor model group, CTX group, and low-,
medium-, and high-dose of ASMq groups.
According to the results, after the administration of
ASMq via gavage, the thymic and splenic weights of all
the experimental groups are increased. In addition, the
hepatic weights of the medium- and high-dose groups
are also increased. The increases in the spleen and thy-
mus indexes reflected enhanced T lymphocyte prolifer-
ation and improved immune function. Usually, the
anti-tumor effects of Chinese herbal medicine are asso-
ciated with immune function regulation [25, 26]. Ac-
cording to Chinese cancer research standards, herbal
medicine is only considered to be effective as an anti-
cancer treatment when the tumor inhibition rate is
higher than 30% [27, 28]. The maximum tumor
inhibition rate of ASMq within the tested dosage range
was not as high as that of the CTX group; however,
both of these substances yielded tumor inhibition rates
greater than 30%, indicating that CTX and ASMq could
both inhibits varying degrees of U27 tumor growth.
Furthermore, the HE staining of the tumor tissue re-
vealed necrosis and various cell sizes in the U27 model
group and improved lesions in the CTX and ASMq
groups. However, the CTX and ASMq groups still ex-
hibited some areas of necrosis and edema. These results
further confirmed the inhibitory effects of ASMq on
U27 tumors.
TGF-β is a multifunctional cytokine that exists in a
wide variety of normal and transformed cells. In fact,
almost all cells are capable of producing TGF-β and
expressing its receptors [29, 30]. TGF-β1 is a key factor
in the regulation of the tumor epithelial-mesenchymal
transition (EMT). TGF-β1, which is involved in cell
proliferation and differentiation as well as the forma-
tion of the extracellular matrix, can promote tumor
growth [31, 32]. According to previous studies, TGF-β1
could reduce the activity of NK cells and promote
tumor cell proliferation and differentiation. Based on
previous researches, high expression levels of TGF-β1
has been observed in a variety of tumors [33, 34]. Ac-
cording to the results of this study, the tumor tissues
obtained from the U27 model group demonstrated
significantly higher levels of TGF-β1 expression than
the CTX group and the low-, medium-, and high-dose
ASMq groups. These findings are consistent with the
high expression rates of TGF-β1 in various malignant
tumors. The decreased expression of TGF-β1 in the
Table 3 ASMq’s effect on the important organ index of in each group mice (n = 8, x  s)
Group Dosage/(g/kg) Thymus index Spleen index Liver index Kidney index
Normal control group - 4.032 ± 0.104 5.929 ± 0.153 56.676 ± 1.570 14.637 ± 0.813
U27 Tumot Model group - 3.578 ± 0.134* 5.288 ± 0.113* 54.585 ± 2.045* 14.034 ± 0.619
CTX group 0.3 2.702 ± 0.360*△ 3.590 ± 0.599*△ 50.088 ± 2.003*△ 14.685 ± 0.812△
ASMq.L group 2 3.641 ± 0.230*△▲ 5.262 ± 0.189*△▲ 52.956 ± 1.934▲ 13.122 ± 0.815*△▲
ASMq.M group 4 3.749 ± 0.203*△▲ 5.780 ± 0.167*△▲ 55.393 ± 2.520▲ 12.802 ± 0.797*△▲
ASMq.H group 8 3.712 ± 0.156*▲ 5.100 ± 0.135*△▲ 54.026 ± 2.271*▲ 12.196 ± 0.503*△▲
Notes:*P < 0.05 compared with Normal control group;△P < 0.05 compared with U27 tumor model group;▲P < 0.05 compared with CTX group
Table 4 ASMq’s effect on the tumor growth of each group mice (n = 8, x  s)
Group Dosage/(g/kg) Tumor weight/mg Tumor inhibition rate/%
Normal control group - 0.000 ± 0.000 -
U27 Tumot Model group - 2102.891 ± 209.690 -
CTX group 0.3 584.273 ± 507.625△ 72.21
ASMq.L group 2 1445.350 ± 327.236△▲ 31.27
ASMq.M group 4 829.930 ± 283.190△▲ 60.53
ASMq.H group 8 1010.540 ± 179.564△▲ 51.94
Notes:△P < 0.05 compared with U27 tumor model group;▲P < 0.05 compared with CTX group
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CTX and ASMq groups possibly relating to its down-
regulation by CTX and ASMq effects. Such as, after
treating liver cancer in mice with tnshinone (Tan) IIA
nanoparticles, significant tumor necrosis occurred and
TGF-β1 expression was decreased, indicating that the
anti-tumor effects of Tan IIA could function by inhibit-
ing TGF-β1 expression [35]. Interestingly, some relating
researches shows that TGF-β could directly or
indirectly inhibits the production of TNF-α [36, 37], in-
dicating that low concentrations of TGF-β were associ-
ated with high concentrations of TNF-α. TNF-α
induces the tumor immune response and cell differenti-
ation, promotes the production of a variety of cytokines
by mononuclear cells and T cells, and induce tumor cell
apoptosis and directly kill tumor cells [38–40]. In our
study, the TNF-α protein expression levels of the low-,
Fig. 1 Pathological examination of mice tumor tissues
Table 5 ASMq’s expression on content of TGF-β1 and TNF-α in the tumor tissues of each group mice (n = 8, x  s)
Group Dosage/(g/kg) TGF-β1 TNF-α
U27 Tumot Model group - 1.4325 ± 0.1715 0.6783 ± 0.0964
CTX group 0.3 1.0561 ± 0.1185△ 0.3370 ± 0.0377△
ASMq.L group 2 0.8537 ± 0.1090△▲ 0.6948 ± 0.0711▲
ASMq.M group 4 0.5770 ± 0.0889△▲ 1.2140 ± 0.1722△▲
ASMq.H group 8 0.5976 ± 0.0864△▲ 1.0199 ± 0.1093△▲
Notes:△P < 0.05 compared with U27 tumor model group;▲P < 0.05 compared with CTX group
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medium-, and high-dose ASMq groups are significantly
higher than those of the U27 model group and CTX
group. Recent studies shows that the anti-tumor effects
of TNF-α were primarily enhanced by the body’s cellu-
lar and humoral immune functions, inhibiting tumor
angiogenesis and directly inducing tumor cell apoptosis
[41, 42]. Serum TNF-α and IL-12 levels has been re-
ported to be increased in tumor-bearing mice treated
with astragalus polysaccharides (APS)-induced mature
dendritic cell (DC) vaccine therapy, suggesting that the
anti-tumor effects of this therapy could stimulates the
immune cells of tumor-bearing mice to produce anti-
tumor cytokines TNF-α and IL-12 [43]. Our research
results also suggests that ASMq shows anti-tumor ef-
fects through stimulating immune cells to produce
anti-tumor cytokines.
Conclusions
In summary, ASMq demonstrates anti-tumor effects and
downregulates the expression of TGF-β1 and upregulates
the expression of TNF-α in vivo. The results of this study
provides a scientific basis for the clinical application of
ASMq in the treatment of cervical cancer.
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